Name	: Mr. S.BHARATH			
PID No.	: MED120619942	Register On : 2	5/03/2023 8:06 AM	
SID No.	: 223004987	Collection On : 2	25/03/2023 11:25 AM	
Age / Sex	: 37 Year(s) / Male	Report On : ;	25/03/2023 7:33 PM	medall
Туре	: OP	Printed On : 0	05/04/2023 5:48 PM	DIAGNOSTICS
Ref. Dr	: MediWheel			
<u>Investiga</u>	ition	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
BLOOD TYPING	GROUPING AND Rh	'O' 'Positive'		
	ood/Agglutination)			
	RETATION: Reconfirm the Blood g	roup and Typing before	e blood transfusion	
<u>Complete</u>	e Blood Count With - ESR			
Haemogle (EDTA Blo	obin ood/Spectrophotometry)	14.4	g/dL	13.5 - 18.0
	Cell Volume(PCV)/Haematocrit	43.8	%	42 - 52
RBC Cou (EDTA Blo	ant ood/Impedance Variation)	4.82	mill/cu.mm	4.7 - 6.0
	rpuscular Volume(MCV) od/Derived from Impedance)	90.9	fL	78 - 100
	rpuscular Haemoglobin(MCH) od/Derived from Impedance)	29.9	pg	27 - 32
concentra	rpuscular Haemoglobin ation(MCHC) ood/Derived from Impedance)	32.9	g/dL	32 - 36
RDW-CV (EDTA Blo	J ood/Derived from Impedance)	13.5	%	11.5 - 16.0
RDW-SD (EDTA Blo) ood/Derived from Impedance)	42.95	fL	39 - 46
	akocyte Count (TC)	6290	cells/cu.mm	4000 - 11000
Neutroph (EDTA Blo <i>Cytometry</i>)	ood/Impedance Variation & Flow	53.7	%	40 - 75
Lymphoc (EDTA Blo <i>Cytometry</i>)	oodImpedance Variation & Flow	35.3	%	20 - 45







APPROVED BY

The results pertain to sample tested.

Page 1 of 8

Name	: Mr. S.BHARATH		
PID No.	: MED120619942	Register On : 25/03/2023 8:06 AM	
SID No.	: 223004987	Collection On : 25/03/2023 11:25 AM	\mathbf{O}
Age / Sex	: 37 Year(s) / Male	Report On : 25/03/2023 7:33 PM	medall
Туре	: OP		DIAGNOSTICS
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Eosinophils (EDTA Blood/Impedance Variation & Flow Cytometry)	4.0	%	01 - 06
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	6.7	%	01 - 10
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.3	%	00 - 02
INTERPRETATION: Tests done on Automated	Five Part cell count	er. All abnormal results	are reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	3.38	10^3 / µl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.22	10^3 / µl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.25	10^3 / µl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.42	10^3 / µl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.02	10^3 / µl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	275	10^3 / µl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	9.6	fL	7.9 - 13.7
PCT (EDTA Blood/Automated Blood cell Counter)	0.26	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	26	mm/hr	< 15







APPROVED BY

The results pertain to sample tested.

Page 2 of 8

Name	: Mr. S.BHARATH		
PID No.	: MED120619942	Register On : 25/03/2023 8:06 AM	
SID No.	: 223004987	Collection On : 25/03/2023 11:25 AM	
Age / Sex	: 37 Year(s) / Male	Report On : 25/03/2023 7:33 PM	medall
Туре	: OP	Printed On : 05/04/2023 5:48 PM	DIAGNOSTICS
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
BUN / Creatinine Ratio	11.28		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	106.5	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine) (Urine - F/GOD - POD)	Negative		Negative
Glucose Postprandial (PPBS) (Plasma - PP/GOD-PAP)	116.8	mg/dL	70 - 140

INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

Urine Glucose(PP-2 hours) (Urine - PP)	Negative		Negative
Blood Urea Nitrogen (BUN) (Serum/Urease UV/derived)	12.3	mg/dL	7.0 - 21
Creatinine (Serum/Modified Jaffe)	1.09	mg/dL	0.9 - 1.3

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin, cefazolin, ACE inhibitors, angiotensin II receptor antagonists, N-acetylcysteine, chemotherapeutic agent such as flucytosine etc.

Uric Acid (Serum/Enzymatic)	4.0	mg/dL	3.5 - 7.2
Liver Function Test			
Bilirubin(Total) (Serum/DCA with ATCS)	0.56	mg/dL	0.1 - 1.2
Venkatrayan T P Lab Manager VERIFIED BY			DR.SUNDAR ELAYAPERUMAL MD, CIC CONSULTANT MICROBIOLOGIST REG NO: 41854

The results pertain to sample tested.

Page 3 of 8

Name	: Mr. S.BHARATH		
PID No.	: MED120619942	Register On	: 25/03/2023 8:06 AM
SID No.	: 223004987	Collection On	: 25/03/2023 11:25 AM
Age / Sex	: 37 Year(s) / Male	Report On	: 25/03/2023 7:33 PM
Туре	: OP	Printed On	: 05/04/2023 5:48 PM DIAGNO

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.18	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.38	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase) (Serum/ <i>Modified IFCC</i>)	18.2	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/ <i>Modified IFCC</i>)	26.2	U/L	5 - 41
GGT(Gamma Glutamyl Transpeptidase) (Serum/ <i>IFCC / Kinetic</i>)	18.0	U/L	< 55
Alkaline Phosphatase (SAP) (Serum/ <i>Modified IFCC)</i>	74.9	U/L	53 - 128
Total Protein (Serum/Biuret)	7.37	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.33	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	3.04	gm/dL	2.3 - 3.6
A : G RATIO (Serum/ <i>Derived</i>)	1.42		1.1 - 2.2
Lipid Profile			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	147.2	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/ <i>GPO-PAP with ATCS</i>)	49.5	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500



Ref. Dr

: MediWheel





APPROVED BY

The results pertain to sample tested.

Page 4 of 8

Name	:	Mr. S.BHARATH					
PID No.	:	MED120619942	Register	On	:	25/03/2023 8:06 AM	
SID No.	:	223004987	Collectio	on On	:	25/03/2023 11:25 AM	
Age / Sex	:	37 Year(s) / Male	Report 0	Dn	:	25/03/2023 7:33 PM	medall
Туре	:	OP	Printed	On	:	05/04/2023 5:48 PM	DIAGNOSTICS
Ref. Dr	:	MediWheel					
<u>Investiga</u>	<u>ati</u>	<u>nc</u>		serve /alue	<u>d</u>	<u>Unit</u>	Biological Reference Interval
increasing variation to	as 50. for	much as 5 to 10 times the fasting There is evidence recommending metabolic syndrome, as non-fasti	levels, just triglycerid	a few les estin	hou mat	rs after eating. Fasting trig tion in non-fasting condition	s change drastically in response to food, glyceride levels show considerable diurnal on for evaluating the risk of heart disease and "circulating level of triglycerides during most
HDL Cho (Serum/Imr		esterol noinhibition)		41.8		mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 40 - 59 High Risk: < 40
LDL Cho (Serum/Ca				95.5		mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL C (Serum/Ca				9.9		mg/dL	< 30
Non HDI (Serum/Ca.	_	Cholesterol lated)		105.4		mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

INTERPRETATION: 1.Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

3.5

Total Cholesterol/HDL Cholesterol	
Ratio	
(Serum/Calculated)	

Venkatrayan T P Lab Manager VERIFIED BY



Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0



APPROVED BY

The results pertain to sample tested.

Page 5 of 8

Name	: Mr. S.BHARATH		
PID No.	: MED120619942	Register On : 25/03/2023 8:06 AM	
SID No.	: 223004987	Collection On : 25/03/2023 11:25 AM	
Age / Sex	: 37 Year(s) / Male	Report On : 25/03/2023 7:33 PM	medall
Туре	: OP	Printed On : 05/04/2023 5:48 PM	DIAGNOSTICS
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/ <i>Calculated</i>)	1.2		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	2.3		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
<u>Glycosylated Haemoglobin (HbA1c)</u>			
HbA1C	5.5	%	Normal: 4.5 - 5.6

(Whole Blood/HPLC)	Prediabetes: 5.7 - 6.4
	Diabetic: $>= 6.5$

Estimated Average Glucose	111.15	mg/dL
(Whole Blood)		

INTERPRETATION: Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values. Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.

THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total	1.41	ng/ml	0.7 - 2.04
(Serum/Chemiluminescent Immunometric Assay			
(CLIA))			

INTERPRETATION:

Comment :

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.





E	ha		-	
1000	ELAYA TANT N REG NO	ICROB	OLOGI	MD, CIC ST

APPROVED BY

The results pertain to sample tested.

Page 6 of 8

Name	: Mr. S.BHARATH			
PID No.	: MED120619942	Register On : 25	5/03/2023 8:06 AM	~
SID No.	: 223004987	Collection On : 2	5/03/2023 11:25 AM	
Age / Sex	: 37 Year(s) / Male	Report On : 2	5/03/2023 7:33 PM	medall
Туре	: OP	Printed On : 0	5/04/2023 5:48 PM	DIAGNOSTICS
Ref. Dr	: MediWheel			
Investiga	<u>ation</u>	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
	xine) - Total emiluminescent Immunometric Assay	9.34	µg/dl	4.2 - 12.0
	RETATION:			
Comment Total T4 va Metabolica	ariation can be seen in other condition	n like pregnancy, drugs	, nephrosis etc. In such ca	ases, Free T4 is recommended as it is
	yroid Stimulating Hormone) emiluminescent Immunometric Assay	1.64	µIU/mL	0.35 - 5.50
Reference 1 st trimes 2 nd trimes 3 rd trimes (Indian Th Comment 1.TSH refe 2.TSH Lev be of the o	erence range during pregnancy deper	, reaching peak levels b as influence on the meas	etween 2-4am and at a m sured serum TSH concent	
<u>Urine An</u>	alysis - Routine			
COLOUI (Urine)	R	Yellow		Yellow to Amber
APPEAR (Urine)	ANCE	Clear		Clear
Protein (Urine/Prot	tein error of indicator)	Negative		Negative
Glucose (Urine/GO)	D - POD)	Negative		Negative
Pus Cells (Urine/Auto	s omated ó"Flow cytometry)	Occasional	/hpf	NIL
	ab Manager Rified BY			DR.SUNDAR ELAYAPERUMAL MD, CIC CONSULTANT MICROBIOLOGIST REG NO. 41854
				APPROVED BY

The results pertain to sample tested.

Page 7 of 8

Name PID No. SID No. Age / Sex Type Ref. Dr	 : Mr. S.BHARATH : MED120619942 : 223004987 : 37 Year(s) / Male : OP : MediWheel 	Collection On 2 Report On 2	5/03/2023 8:06 AM 5/03/2023 11:25 AM 5/03/2023 7:33 PM 5/04/2023 5:48 PM	DIAGNOSTICS
<u>Investiga</u>	ation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Epithelia (Urine/Auto	l Cells omated ó"Flow cytometry)	Occasional	/hpf	NIL
RBCs (Urine/Auto	omated 6"Flow cytometry)	NIL	/hpf	NIL
Casts (Urine/Auto	omated 6"Flow cytometry)	NIL	/hpf	NIL
Crystals (Urine/Auto	omated ó"Flow cytometry)	NIL	/hpf	NIL
Others		NIL		

(Urine)

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.





-- End of Report --



APPROVED BY

VERIFIED BY

The results pertain to sample tested.

Page 8 of 8